Feinsod Matthew 4

What Happened
Matthew Feinsod, Chief Medical Officer of Kalaris Therapeutics (KLRS), received a derivative equity award on March 19, 2026: 135,000 shares/options reported at $0.00 per share. This filing reports an award/grant (transaction code A), not an open‑market purchase or sale — i.e., Feinsod was granted the right to receive these shares subject to vesting rather than immediately acquiring free‑trading shares.

Key Details

• Transaction date: March 19, 2026; Form 4 filed March 20, 2026 (timely filing).
• Reported amount: 135,000 shares (derivative/option) at $0.00 per share as reported on the form.
• Shares owned after transaction: not specified in the provided filing.
• Footnote: Options granted on March 19, 2026 vest over four years — 25% vest on March 19, 2027, with the remainder vesting in equal monthly installments thereafter, subject to continuous service.
• Filing timeliness: filed the next day (appears timely; not marked late).

Context
This is an equity award (derivative/option grant), not an immediate purchase or sale. Because the award vests over four years, Feinsod must remain employed/perform services for the award to vest; the filing does not indicate any immediate exercise or sale. The $0.00 price reported on the Form 4 reflects how the grant was reported on the form and does not by itself indicate the economic value or future exercise terms beyond the stated vesting schedule.